Polarization of tumor-associated macrophage is associated with tumor vascular normalization by endostatin

Thoracic Cancer

Volumn 4, Issue 3, 2013, Pages 295-305

  Peng, Qian ^a   Li, Mei ^a   Wang, Zi ^a   Jiang, Ming ^a   Yan, Xi ^a   Lei, Song ^a   Zhang, Hui ^a   Zhang, Wei ^a   Liu, Yan Yang ^a   Luo, Feng ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Endostatin; Normalization; Tumor vasculature; Tumor associated macrophages

Indexed keywords

ENDOSTATIN; HISTIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASEMENT MEMBRANE; CELL INFILTRATION; CONTROLLED STUDY; FLOW CYTOMETRY; FROZEN SECTION; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOFLUORESCENCE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MACROPHAGE; MONOCYTE; MOUSE; NECROSIS; NONHUMAN; PERICYTE; PHENOTYPE; POLARIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSMISSION ELECTRON MICROSCOPY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; WESTERN BLOTTING;

EID: 84881515226     PISSN: 17597706     EISSN: 17597714     Source Type: Journal    
DOI: 10.1111/1759-7714.12018     Document Type: Article

References (48)

1. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-257.
2. Fukumura D, Jain RK. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem 2007; 101: 937-949.
3. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7: 987-989.
4. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004; 64: 3731-3736.
5. Batchelor TT, Sorensen AG, di Tomaso E etal. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11: 83-95.
6. Dings RP, Loren M, Heun H etal. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res 2007; 13: 3395-3402.
7. Ning T, Jiang M, Peng Q etal. Low-dose endostatin normalizes the structure and function of tumor vasculature and improves the delivery and anti-tumor efficacy of cytotoxic drugs in a lung cancer xenograft murine model. Thoracic Cancer 2012; 3: 229-238.
8. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005; 5: 953-964.
9. Pollard JW. Trophic macrophages in development and disease. Nat Rev Immunol 2009; 9: 259-270.
10. Ding T, Xu J, Wang F etal. High tumor infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection. Hum Pathol 2009; 40: 381-389.
11. Lee CH, Espinosa I, Vrijaldenhoven S etal. Prognostic significance of macrophage infiltration in leiomyosarcomas. Clin Cancer Res 2008; 14: 1423-1430.
12. Jensen TO, Schmidt H, Møller HJ etal. Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. J Clin Oncol 2009; 27: 3330-3337.
13. Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 2009; 27: 451-483.
14. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010; 22: 231-237.
15. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010; 141: 39-51.
16. Rolny C, Mazzone M, Tugues S etal. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PIGF. Cancer Cell 2011; 19: 31-44.
17. Huang Y, Snuderl M, Jain RK. Polarization of tumor-associated macrophages: a novel strategy for vascular normalization and antitumor immunity. Cancer Cell 2011; 19: 1-2.
18. Dineen SP, Lynn KD, Holloway SE etal. Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice. Cancer Res 2008; 68: 4340-4346.
19. Roland CL, Dineen SP, Lynn KD etal. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Mol Cancer Ther 2009; 8: 1761-1771.
20. Folkman J. Antiangiogenesis in cancer therapy - endostatin and its mechanisms of action. Exp Cell Res 2006; 312: 594-607.
21. Huang G, Chen L. Recombinant human endostatin improves anti-tumor efficacy of paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma. J Cancer Res Clin Oncol 2010; 136: 1201-1211.
22. Peng F, Xu Z, Wang J etal. Recombinant human endostatin normalizes tumor vasculature and enhances radiation response in xenografted human nasopharyngeal carcinoma models. PLoS ONE 2012; 7: e34646.
23. Zhou Q, Guo P, Gallo JM. Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide. Clin Cancer Res 2008; 14: 1540-1549.
24. Holopainen T, Saharinen P, D'Amico G etal. Effects of angiopoietin-2-blocking antibody on endothelial cell-cell junctions and lung metastasis. J Natl Cancer Inst 2012; 104: 461-475.
25. Ljungkvist AS, Bussink J, Kaanders JH etal. Hypoxic cell turnover in different solid tumor lines. Int J Radiat Oncol Biol Phys 2005; 62: 1157-1168.
26. Navarro-Alvarez N, Kondo E, Kawamoto H etal. Isolation and propagation of a human CD133 (-) colon tumor-derived cell line with tumorigenic and angiogenic properties. Cell Transplant 2010; 19: 865-877.
27. Pelleitier M, Montplaisir S. The nude mouse: a model of deficient T-cell function. Methods Achiev Exp Pathol 1975; 7: 149-166.
28. Shankaran V, Ikeda H, Bruce AT etal. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410: 1107-1111.
29. Ling C, Xie Y, Zhao D, Zhu Y, Xiang J, Yang J. Enhanced radiosensitivity of non-small-cell lung cancer (NSCLC) by adenovirus-mediated ING4 gene therapy. Cancer Gene Ther 2012; 19: 697-706.
30. Wentworth PA, Ziegler HK. Induction of macrophage Ia expression by lipopolysaccharide and Listeria monocytogenes in congenitally athymic nude mice. J Immunol 1987; 138: 3167-3173.
31. Mogensen SC, Andersen HK. Role of activated macrophages in resistance of congenitally athymic nude mice to hepatitis induced by herpes simplex virus type 2. Infect Immun 1978; 19: 792-798.
32. Croy BA, Linder KE, Yager JA. Primer for non-immunologists on immune-deficient mice and their applications in research. Comp Med 2001; 51: 300-313.
33. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004; 25: 677-686.
34. Augustin HG, Koh GY, Thurston G, Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 2009; 10: 165-177.
35. Pucci F, Venneri MA, Biziato D etal. A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood "resident" monocytes, and embryonic macrophages suggests common functions and developmental relationships. Blood 2009; 114: 901-914.
36. Venneri MA, De Palma M, Ponzoni M etal. Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood 2007; 109: 5276-5285.
37. Jain RK. Normalization of tumor vasculature: an emerging concept in anti-angiogenic therapy. Science 2005; 307: 58-62.
38. Goel S, Duda DG, Xu L etal. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011; 91: 1071-1121.
39. Winkler F, Kozin SV, Tong RT etal. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004; 6: 553-563.
40. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003; 9: 685-693.
41. Chae SS, Kamoun WS, Farrar CT etal. Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas. Clin Cancer Res 2010; 16: 3618-3627.
42. Hamzah J, Jugold M, Kiessling F etal. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 2008; 453: 410-414.
43. Mazzone M, Dettori D, Leite de Oliveira R etal. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 2009; 136: 839-851.
44. Abdollahi A, Hahnfeldt P, Maercker C etal. Endostatin's antiangiogenic signaling network. Mol Cell 2004; 13: 649-663.
45. Faye C, Chautard E, Olsen BR, Ricard-Blum S. The first draft of the endostatin interaction network. J Biol Chem 2009; 284: 22041-22047.
46. Shi H, Huang Y, Zhou H etal. Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin. Blood 2007; 110: 2899-2906.
47. Klenotic PA, Huang P, Palomo J etal. Histidine-rich glycoprotein modulates the anti-angiogenic effects of vasculostatin. Am J Pathol 2010; 176: 2039-2050.
48. Thulin A, Ringvall M, Dimberg A etal. Activated platelets provide a functional microenvironment for the antiangiogenic fragment of histidine-rich glycoprotein. Mol Cancer Res 2009; 7: 1792-1802.